Lameire Norbert
University Hospital , 185, De Pintelaan, Gent 9000 , Belgium.
Clin Kidney J. 2014 Feb;7(1):11-22. doi: 10.1093/ckj/sft135. Epub 2013 Nov 26.
Cancer patients may develop a variety of kidney lesions that impair not only their immediate survival but also limit the adequate treatment of the underlying malignant process. This review summarizes the nephrotoxic potential of some of the most recently developed anti-cancer drugs, focusing on those interfering with the vascular endothelial growth factor and epidermal growth factor receptor pathways and mammalian target of rapamycin inhibitors. Thrombotic microangiopathy (haemolytic-uraemic syndrome), proteinuria, hypertension and magnesium depletion are the most common side effects. Also the risk for developing acute kidney injury in patients with advanced prostate cancer undergoing androgen deprivation therapy is discussed.
癌症患者可能会出现多种肾脏病变，这些病变不仅会影响他们的近期生存，还会限制对潜在恶性疾病的充分治疗。本综述总结了一些最新研发的抗癌药物的肾毒性潜力，重点关注那些干扰血管内皮生长因子和表皮生长因子受体途径以及雷帕霉素靶蛋白抑制剂的药物。血栓性微血管病（溶血尿毒综合征）、蛋白尿、高血压和镁缺乏是最常见的副作用。此外，还讨论了晚期前列腺癌患者接受雄激素剥夺治疗时发生急性肾损伤的风险。
